

## **Claim Amendments**

Claims 1-32 (cancelled)

33. (Pending): A method for the treatment of thrombotic diseases or conditions comprising administering a therapeutically effective amount of a proteolytically active NP which is at least about 80% homologous by amino acid sequence with reference sequence thrombin and has a ratio of protein C activating activity to fibrinogen clotting activity that is greater than about twice that of reference sequence thrombin.

34. (Pending): The method of claim 33 wherein the NP possesses greater than about twice the residual proteolytic activity of reference thrombin when measured by hydrolysis of S-2238 in the presence of heparin-dependent AT-III inhibition.

35. (Pending): The method of claim 33 wherein the thrombotic disease or condition is cardiac bypass surgery.

36. (Pending): The method of claim 33 wherein the NP is devoid of detectable fibrinogen clotting activity.

37. (Pending): The method of claim 36 wherein the NP retains at least about 5% of wild-type thrombin protein C activating activity.

38. (Pending): The method of claim 37 wherein the NP is K52A, R233A NP, E229D NP, E229F NP, E229S NP, E229W NP, E229Y NP, R233D NP, R233N NP, R233F NP, W50C NP, K52C NP, W50E NP, or W50K NP.